home / stock / cmvlf / cmvlf news

CMVLF News and Press, Cellectis Romainville Ord From 05/06/25

Stock Information
Company Name: Cellectis Romainville Ord
Stock Symbol: CMVLF
Market: OTC
Website: cellectis.com
Menu
CMVLF CMVLF Quote CMVLF Short CMVLF News CMVLF Articles CMVLF Message Board
Get CMVLF Alerts

News, Short Squeeze, Breakout and More Instantly...
CMVLF - Cellectis to Report First Quarter Financial Results on May 12, 2025

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financia...
CMVLF - Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®...

CMVLF - Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript

2025-03-14 10:36:24 ET Cellectis S.A. (CLLS) Q4 2024 Earnings Conference Call March 14, 2025, 08:00 AM ET Company Participants Arthur Stril - CFO and Chief Business Officer Andre Choulika - CEO Adrian Kilcoyne - CMO Conference Call Participants Gena W...

CMVLF - Cellectis Non-GAAP EPS of -$0.16 beats by $0.05, revenue of $33.22M beats by $23.63M

2025-03-14 00:53:35 ET More on Cellectis Cellectis S.A announces potential resale of up to 44M shares Seeking Alpha’s Quant Rating on Cellectis Historical earnings data for Cellectis Financial information for Cellectis Read the full article o...
CMVLF - Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL. ○ U...

CMVLF - Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report f...

CMVLF - Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcases an innovative strategy for T cel...
Previous 10 Next 10